低分子肝素钙在原发性肾病综合征伴高凝状态患者中的应用价值

目的探讨低分子肝素钙在原发性肾病综合征伴高凝状态患者中的应用价值。方法选取60例原发性肾病综合征伴高凝状态患者，随机均分为对照组和观察组，对照组给予双嘧达莫片治疗，观察组给予低分子肝素钙治疗。比较两组患者治疗前后尿蛋白定量、血清胆固醇、血清白蛋白、PT、APTT和D—D值的差异。结果两组患者治疗前各指标比较差异无统计学意义（P〉0．05），治疗后观察组尿蛋白定量、血清胆固醇、血清白蛋白和D—D值均显著优于对照组（P〈0．05），观察组PT和APTT分别为（12．5±2．2）s和（35．9±7．1）s，均显著高于对照组的（10．1±1．9）s和、（30．8±7．3）S（P〈0．05）。结论低分子肝素钙治疗原发性肾病综合征伴高凝状态患者疗效确切，可显著改善高凝状态，降低蛋白尿。

Analysis on clinical value of low molectdar weight heparin for the treatment of primary nephrotic syndrome associated with a hypercoagulable state

Objective To investigate the clinical value of low molecular weight heparin for the treatment of primary nephrotic syndrome associated with a hypercoagulable state. Methods 60 cases of primary nephrotic syndrome associated with a hypercoagulable state in our hospital were randomly divided into control group and observation group. The control group was treated with dipyridamole tablets. The observation group was treated with low molecular weight heparin. The urinary protein, serum cholesterol, albumin, PT, APTT and DD before and after treatment of two groups were compared. Results Each index of two groups before treatment had no significant difference （P 〉 0.05）. The urinary protein, serum cholesterol, albumin and DD of observation group after treatment were significantly better than those of control group （P 〈 0.05）. PT and APTT of observation group were （12.5 ± 2.2）s and （35.9 ± 7.1）s respectively, which were significantly higher than those of control group as （10.1 ± 1.9）s and （30.8 ± 7.3）s （P 〈 0.05）. Conclusion Low molecular weight heparin for primary nephrotic syndrome associated with a hypercoagulable state has exact effect. It can significantly improve hypercoagulable state and reduce proteinuria.